Rankings
▼
Calendar
DNLI FY 2021 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena
DNLI
Denali Therapeutics Inc.
$3B
FY 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$49M
-85.5% YoY
Gross Profit
$49M
100.0% margin
Operating Income
-$296M
-607.8% margin
Net Income
-$291M
-597.2% margin
EPS (Diluted)
$-2.39
Cash Flow
Operating Cash Flow
-$211M
Free Cash Flow
-$220M
Stock-Based Comp.
$85M
Balance Sheet
Total Assets
$1.4B
Total Liabilities
$442M
Stockholders' Equity
$962M
Cash & Equivalents
$293M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$49M
$336M
-85.5%
Gross Profit
$49M
$336M
-85.5%
Operating Income
-$296M
$63M
-571.6%
Net Income
-$291M
$71M
-508.5%
← Q4 2020
All Quarters
Q1 2021 →